Yuhans new drug Leclaza on track to become global blockbuster - Pulse by Maeil Business News Korea - Pulse News
| 000100 Stock | 129,800 7,900 6.48% |
About 54% of Yuhan's investors are presently thinking to get in. The analysis of current outlook of investing in Yuhan suggests that some traders are interested regarding Yuhan's prospects. The current market sentiment, together with Yuhan's historical and current headlines, can help investors time the market. In addition, many technical investors use Yuhan stock news signals to limit their universe of possible portfolio assets.
Yuhan |
Yuhans new drug Leclaza on track to become global blockbuster - Pulse by Maeil Business News Korea Pulse News
Read at news.google.com
 |
Yuhan Fundamental Analysis
We analyze Yuhan's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Yuhan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Yuhan based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Yuhan is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Yuhan Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Yuhan stock to make a market-neutral strategy. Peer analysis of Yuhan could also be used in its relative valuation, which is a method of valuing Yuhan by comparing valuation metrics with similar companies.
Peers
Yuhan Related Equities
| 030210 | KTB Investment | 1.51 | ||||
| 019550 | SBI Investment | 1.37 | ||||
| 005940 | NH Investment | 0.20 | ||||
| 900310 | Coloray International | 0.12 | ||||
| 032850 | BIT Computer | 0.51 | ||||
| 034220 | LG Display | 0.77 | ||||
| 298690 | Air Busan | 1.33 | ||||
| 027360 | Aju IB | 3.43 |
Complementary Tools for Yuhan Stock analysis
When running Yuhan's price analysis, check to measure Yuhan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Yuhan is operating at the current time. Most of Yuhan's value examination focuses on studying past and present price action to predict the probability of Yuhan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Yuhan's price. Additionally, you may evaluate how the addition of Yuhan to your portfolios can decrease your overall portfolio volatility.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Global Correlations Find global opportunities by holding instruments from different markets |